HAVCR2 and neoplasm: PD-1, CTLA-4, TIM-3, LAG-3, TIGIT immune checkpoints and PD-L1, and galactin-9 ligands were selected due to their important role in tumor immune evasion and their potential as therapeutic targets for immune-mediated therapies.